Theravance Biopharma (TBPH) Cash from Operations Growth (1y) (2014 - 2026)
Theravance Biopharma (TBPH) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
- |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
- |
| 10 |
Theravance Biopharma |
835.85 Mn |
441.18 Mn |
- |
70.26% |
| Date | Value |
|---|
| Mar 31, 2026 |
70.26% |
| Dec 31, 2025 |
-572.28% |
| Sep 30, 2025 |
-25.25% |
| Jun 30, 2025 |
4,812.89% |
| Mar 31, 2025 |
4,311.25% |
| Dec 31, 2024 |
-5.62% |
| Sep 30, 2024 |
-109.01% |
| Jun 30, 2024 |
64.50% |
| Mar 31, 2024 |
90.89% |
| Dec 31, 2023 |
99.31% |
| Sep 30, 2023 |
88.96% |
| Jun 30, 2023 |
13.28% |
| Mar 31, 2023 |
56.96% |
| Dec 31, 2022 |
-192.35% |
| Sep 30, 2022 |
50.43% |
| Jun 30, 2022 |
71.38% |
| Mar 31, 2022 |
62.69% |
| Dec 31, 2021 |
34.64% |
| Sep 30, 2021 |
41.00% |
| Jun 30, 2021 |
6.06% |
